Physician profile
Patrick M Garrison
NPI 1598806663
$10,094.06
in general payments reported to CMS, 2019-2025
50 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,970 · 2020: $1,075 · 2021: $1,763 · 2022: $1,652 · 2023: $1,171 · 2024: $1,281 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,634.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,478.11 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,415.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,062.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,004.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $650.77 | 2019-2025 | |
| Abbvie INC. | $644.00 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $599.21 | 2019-2025 | Jardiance |
| Amgen INC. | $443.84 | 2019-2024 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $357.36 | 2020-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $318.13 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $229.33 | 2019-2023 | Verquvo, Segluromet, Steglujan |
| Biohaven Pharmaceutical Holding Company LTD. | $132.68 | 2022 | |
| Supernus Pharmaceuticals, INC. | $122.97 | 2021-2024 | Qelbree, Qelbree |
| Amarin Pharma, INC. | $115.99 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $113.85 | 2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Garrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.